New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
12:26 EDTALNYAlnylam presents new pre-clinical data on RNAi therapeutics
Alnylam Pharmaceuticals announced that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemoglobinopathies at the 54th American Society of Hematology Annual Meeting being held December 8-11, 2012 in Atlanta. Alnylam scientists presented data showing that ALN-TMP, an RNAi therapeutic targeting Tmprss6, leads to disease modifying effects, including a correction in globin gene expression, in a model of ß-thalassemia. These studies were conducted in collaboration with Boston Children’s Hospital. Alnylam’s program in hemoglobinopathies comprises part of its ‘Alnylam 5x15™’ product strategy, by which the company aims to advance five programs in clinical development, including programs in advanced stages, by the end of 2015.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2015
08:18 EDTALNYAlnylam data encouraging, says JMP Securities
Subscribe for More Information
April 13, 2015
11:02 EDTALNYAlnylam publishes pre-clinical results on ALN-AT3
Subscribe for More Information
10:15 EDTALNYHigh option volume stocks
Subscribe for More Information
April 8, 2015
06:57 EDTALNYAlnylam added to short-term buy list at Deutsche Bank

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use